Selligence

Repligen

Company Information

Repligen is a biopharmaceutical company developing consumable products for the manufacture of biological drugs.


Industries:
Biotechnology
Consumer Goods
Technology, Hardware and Equipment
Government and Military
Science and Engineering
Manufacturing
Industrial
Corporate Supplies and Printing
Pharmaceuticals and Life Sciences
Health Care
Aerospace and Defence
Electrical Engineering
Data and Analytics
Locations:
Waltham
California, Md
Irving, Tx
Breda
Long Beach, Ca
Lund
Ravensburg
Clifton, Nj
Simi Valley, Ca
Bridgewater, Nj
Rancho Murieta, Ca
Singapore
Bengaluru
Auburn, Wa
crunchbase:http://www.crunchbase.com/organization/repligen
twitter:https://www.twitter.com/i/flow/login?redirect_after_login=%2frepligen
linkedin:https://www.linkedin.com/company/repligen-corporation
homepage:https://repligen.com
Emailinvestors@repligen.com
Description:
Repligen Corporation is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of Protein A resins that are used to separate and purify monoclonal antibody therapeutics. Our ATF (Alternating Tangential Flow) systems and our growth factor products are used to increase product yield during the fermentation stage of biologic drug manufacturing. In addition, we developed and market an innovative line of “ready-to-use” chromatography columns under our OPUS® and MediaScout® brands that we deliver pre-packed with our customers’ choice of resin. Repligen’s corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Lund, Sweden and Weingarten, Germany.
Stock Code:NASDAQ:RGEN

Employees

Number of employees
1001-5000

Trends

Last 4 weeks

Last 3 months
DivestingInvesting

Recent Events

News
Job Posting
Other News
See All news